Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
The prostaglandin analogue latanoprost, the most commonly prescribed treatment for glaucoma, can greatly reduce risk of vision loss in people with open-angle glaucoma, found a placebo-controlled trial of 516 patients (Garway-Heath DF et al. Lancet.doi:10.1016/S0140-6736(14)62111-5 [published online December 18, 2014]).
Half of the 516 newly diagnosed and previously untreated patients with open-angle glaucoma were randomly assigned to receive daily intraocular-lowering treatment with latanoprost and the other half to receive placebo eyedrops. Participants had intraocular pressure measurements, retinal imaging, and 16 visual field tests to identify glaucoma-induced deterioration over the study’s 2-year period.
Slomski A. Glaucoma Drug Significantly Slows the Progression of Vision Loss. JAMA. 2015;313(8):786. doi:10.1001/jama.2015.0721
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: